Kobayashi Yuka, Nagashima Wataru, Tokura Tatsuya, Yoshida Keizo, Umemura Eri, Miyauchi Tomoya, Arao Munetaka, Ito Mikiko, Kimura Hiroyuki, Kurita Kenichi, Ozaki Norio
*Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, †Health Care Promotion Division, DENSO Corporation, Kariya, Aichi; and ‡Department of Oral and Maxillofacial Surgery, School of Dentistry, Aichi Gakuin University, Nagoya, Japan.
Clin Neuropharmacol. 2017 Jul/Aug;40(4):163-168. doi: 10.1097/WNF.0000000000000225.
The purpose of this study was to examine the relationship between the pain-relieving effects of duloxetine and its plasma concentrations in patients with burning mouth syndrome and atypical odontalgia characterized by chronic nonorganic pain in the orofacial region.
We administered duloxetine to 77 patients diagnosed as having burning mouth syndrome or atypical odontalgia for 12 weeks. The initial dose of duloxetine was established as 20 mg/d and was increased to 40 mg/d after week 2. We evaluated pain using the visual analog scale and depressive symptoms using the Structured Interview Guide for the Hamilton Depression Rating Scale at weeks 0, 2, 4, 6, 8, 10, and 12 and measured plasma concentrations of duloxetine 12 weeks after the start of its administration.
Visual analog scale scores were significantly lower 12 weeks after than at the start of the administration of duloxetine (paired t test, t = 6.65, P < 0.0001). We examined the relationship between the rate of decreases in visual analog scale scores and plasma concentrations of duloxetine. There was no significant linear regression or quadratic regression.
Duloxetine significantly relieved pain in patients with chronic nonorganic pain in the orofacial region. However, no relationship was observed between its pain-relieving effects and plasma concentrations.
本研究旨在探讨度洛西汀在以口腔面部慢性非器质性疼痛为特征的灼口综合征和非典型牙痛患者中的镇痛效果与其血浆浓度之间的关系。
我们对77例被诊断为灼口综合征或非典型牙痛的患者给予度洛西汀治疗，为期12周。度洛西汀的初始剂量设定为20mg/d，在第2周后增加至40mg/d。我们在第0、2、4、6、8、10和12周使用视觉模拟量表评估疼痛，并使用汉密尔顿抑郁量表结构化访谈指南评估抑郁症状，在度洛西汀给药开始12周后测量其血浆浓度。
度洛西汀给药12周后的视觉模拟量表评分显著低于给药开始时（配对t检验，t = 6.65，P < 0.0001）。我们研究了视觉模拟量表评分下降率与度洛西汀血浆浓度之间的关系。未发现显著的线性回归或二次回归。
度洛西汀可显著缓解口腔面部慢性非器质性疼痛患者的疼痛。然而，未观察到其镇痛效果与血浆浓度之间的关系。
